PKD2 and hepatocellular carcinoma: Active PKD2 binds to the p110α and p85 subunits of PI3K and stimulates the PI3K/AKT signaling pathway, which, in turn, phosphorylates GSK3β on its inhibitory phosphorylation sites, thus inducing the accumulation of β-catenin in the nucleus, which stimulates the expression of N-cadherin and vimentin mesenchymal markers and suppresses the expression of E-cadherin and ZO-1 epithelial markers, thus promoting HCC EMT and invasion [99].